Investor Presentaiton

| Committed to Long-term Growth & Shareholder Returns Takeda 11 Near-term (FY2022-2023) • Growth & Launch Products expected to mitigate near- term Loss of Exclusivities (e.g. VELCADE & VYVANSE) Medium-term (FY2024 - early 2030s) • Continued expansion of Growth & Launch Products • Late-stage pipeline launches • Limited LOE exposure until Entyvio biosimilars launch Long-term (FY2030s and beyond) • Additional contribution from clinical pipeline of ~40 NMES Robust research engine Continued Pipeline Enhancement Supported by a Solid Financial Foundation

View entire presentation